Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease-Reference-Cited by-同舟云学术

Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease

Published:2022-09-12 Issue: Volume: Page:1-8
ISSN:0167-6830
Container-title:Orbit
language:en
Short-container-title:Orbit

Author:

Ting Michelle A.¹,Ozzello Daniel James¹,Topilow Nicole J.¹,Yoon Jin Sook¹²,Liu Catherine Y.¹,Korn Bobby S.¹³,Kikkawa Don O.¹³

Affiliation:

1. Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA

2. Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea

3. Division of Plastic and Reconstructive Surgery, Department of Surgery, UC San Diego, La Jolla, California, USA

Funder

funding

Publisher

Informa UK Limited

Subject

Ophthalmology

Link

https://www.tandfonline.com/doi/pdf/10.1080/01676830.2022.2122515

Reference18 articles.

1. Teprotumumab for the Treatment of Active Thyroid Eye Disease

2. Early experience with teprotumumab for chronic thyroid eye disease

3. Teprotumumab for chronic thyroid eye disease

4. The Initial Clinical Characteristics of Graves' Orbitopathy Vary With Age and Sex

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orbital decompression following treatment with teprotumumab for thyroid eye disease;Canadian Journal of Ophthalmology;2024-07

2. Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease;Ophthalmic Plastic & Reconstructive Surgery;2024-05-09

3. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease;Orbit;2023-11-17

4. Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease;Ophthalmic Plastic & Reconstructive Surgery;2023-11-16

5. Re: “Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease”;Ophthalmic Plastic & Reconstructive Surgery;2023-07